Interagency Coordinating Committee on the Validation of Alternative Methods; Notice of Public Meeting; Request for Public Input, 38906-38907 [2024-10061]
Download as PDF
38906
Federal Register / Vol. 89, No. 90 / Wednesday, May 8, 2024 / Notices
Dated: May 2, 2024.
B. Kaye Hayes,
Deputy Assistant Secretary for Infectious
Disease, Department of Health and Human
Services.
[FR Doc. 2024–10006 Filed 5–7–24; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee
on the Validation of Alternative
Methods; Notice of Public Meeting;
Request for Public Input
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Interagency Coordinating
Committee on the Validation of
Alternative Methods (ICCVAM) will
hold a public forum to share
information and facilitate direct
communication of ideas and suggestions
from stakeholders. Interested persons
may attend in person or view the
meeting remotely by webcast. Time will
be set aside for questions and public
statements on the topics discussed.
Registration is requested for attending in
person and required for viewing the
webcast. Registration is also required for
presenting oral statements, whether in
person or online. Information about the
meeting and registration are available at
https://ntp.niehs.nih.gov/go/
iccvamforum-2024.
DATES:
Meeting: May 20, 2024, 1 p.m. to
approximately 5 p.m. EDT; Tuesday,
May 21, 2024, 9 a.m. to approximately
4:30 p.m. EDT.
Registration for Onsite Meeting:
Deadline is May 17, 2024.
Registration for Webcast: Deadline is
May 21, 2024.
Registration for Oral Statements:
Deadline is May 15, 2024.
Registration to attend in person is
requested; registration to view the
webcast and to present oral public
statements (in person or online) is
required.
ADDRESSES:
Meeting Location: William H. Natcher
Conference Center, National Institutes of
Health (NIH), Bethesda, MD 20892.
Meeting web page: Registration and
other meeting materials are at https://
ntp.niehs.nih.gov/go/iccvamforum2024. A preliminary agenda will be
posted on this page by May 3.
FOR FURTHER INFORMATION CONTACT: Dr.
Nicole Kleinstreuer, Director, National
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:03 May 07, 2024
Jkt 262001
Toxicology Program Interagency Center
for the Evaluation of Alternative
Toxicological Methods (NICEATM),
email: nicole.kleinstreuer@nih.gov,
telephone: 984–287–3150.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM, a
congressionally mandated committee,
coordinates the development and
validation of alternative testing
strategies that protect human health and
the environment while replacing,
reducing, or refining animal use.
ICCVAM’s goals include promotion of
national and international partnerships
between governmental and
nongovernmental groups, including
academia, industry, advocacy groups,
and other key stakeholders. To foster
these partnerships ICCVAM initiated
annual public forums in 2014 to share
information and facilitate direct
communication of ideas and suggestions
from stakeholders (79 FR 25136).
This year’s meeting will be held on
May 20 and 21, 2024. NICEATM and
ICCVAM members will give
presentations on current activities
related to the development and
validation of alternative test methods
and approaches.
There will be opportunities for
participants to ask clarifying or followup questions of the ICCVAM members
about their presentations. Instructions
for submitting these questions will be
provided to webcast viewers prior to the
event. The agenda will also include time
for public oral statements relevant to the
ICCVAM mission and current activities
from participants who have registered to
do so in advance.
Preliminary Agenda and Other
Meeting Information: A preliminary
agenda will be posted by May 3 at
https://ntp.niehs.nih.gov/go/
iccvamforum-2024. Interested
individuals are encouraged to visit this
web page to stay abreast of the most
current meeting information.
Meeting and Registration: This
meeting is open to the public. The
public may attend the meeting at NIH,
where attendance is limited only by the
space available, or view remotely by
webcast. Those planning to attend the
meeting in person are encouraged to
register at https://ntp.niehs.nih.gov/go/
iccvamforum-2024 by May 15, 2024, to
facilitate planning for appropriate
meeting space. Registration for the
webcast is required and is open through
4:30 p.m. EDT on May 21, 2024, at
https://ntp.niehs.nih.gov/go/
iccvamforum-2024. Registrants will
receive instructions on how to access
and participate in the webcast in the
email confirming their registration.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
NIH visitor and security information
is available at https://www.nih.gov/
about/visitor/index.htm. Individuals
with disabilities who need
accommodation to participate in this
event should contact Nicole
Kleinstreuer at phone: 919–407–1609 or
email: nicole.kleinstreuer@nih.gov. TTY
users should contact the Federal TTY
Relay Service at 800–877–8339.
Requests should be made at least five
business days in advance of the event.
Request for Oral Public Statements: In
addition to time for clarifying or followup questions following scheduled
presentations, time will be allotted
during the meeting for oral public
statements with associated slides on
topics relevant to ICCVAM’s mission.
Separate registration for those wishing
to provide public statements is required
and is open through May 15, 2024, at
https://ntp.niehs.nih.gov/go/
iccvamforum-2024. Any meeting
attendee or webcast viewer may ask
clarifying questions during the
appropriate times in the agenda. The
additional registration is only required
for those who wish to give separate
public statements. The number and
length of presentations may be limited
based on available time. Submitters will
be identified by their name and
affiliation and/or sponsoring
organization, if applicable. Participants
registered to present oral public
statements must email their statement to
ICCVAMquestions@niehs.nih.gov by
May 15, 2024, to allow time for review
by NICEATM and ICCVAM and posting
to the meeting page prior to the forum.
Persons submitting public statements
and/or associated slides should include
their name, affiliation (if any), mailing
address, telephone, email, and
sponsoring organization (if any) with
the document. Guidelines for public
statements are at https://
ntp.niehs.nih.gov/ntp/about_ntp/
guidelines_public_comments_508.pdf.
Persons presenting oral public
statements will be contacted to arrange
the logistics of their presentations.
Presenters should plan for their
presentation to run seven minutes or
less; each public statement presentation
will be followed by up to three minutes
to allow for clarifying or follow-up
questions. Time allotted for
presentations and follow-up questions
may be reduced depending on the time
available.
Written statements on topics relevant
to ICCVAM’s mission may be submitted
to support an oral public statement or as
standalone documents. These should be
emailed to ICCVAMquestions@
niehs.nih.gov by May 15, 2024. Public
statements received prior to the May 15
E:\FR\FM\08MYN1.SGM
08MYN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 90 / Wednesday, May 8, 2024 / Notices
deadline will be distributed to
NICEATM and ICCVAM members
before the meeting. Written public
statements received after the deadline
may be reviewed by NICEATM and
ICCVAM at a future date. Materials
submitted to accompany oral public
statements or standalone written
statements should include the
submitters name, affiliation (if any),
mailing address, telephone, email, and
sponsoring organization (if any) with
the document. Guidelines for public
statements are at https://ntp.niehs.
nih.gov/ntp/about_ntp/guidelines_
public_comments_508.pdf.
Responses to this notice are
voluntary. No proprietary, classified,
confidential, or sensitive information
should be included in statements
submitted in response to this notice or
presented during the meeting. This
request for input is for planning
purposes only and is not a solicitation
for applications or an obligation on the
part of the U.S. Government to provide
support for any ideas identified in
response to the request. Please note that
the U.S. Government will not pay for
the preparation of any information
submitted or for its use of that
information.
Background Information on ICCVAM
and NICEATM: ICCVAM is an
interagency committee composed of
representatives from 17 Federal
regulatory and research agencies that
require, use, generate, or disseminate
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
safety and hazards of chemicals and
products and replace, reduce, or refine
animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of the National Institute of
Environmental Health Sciences and
provides the authority for ICCVAM
involvement in activities relevant to the
development of alternative test
methods. Additional information about
ICCVAM can be found at https://
ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
VerDate Sep<11>2014
17:03 May 07, 2024
Jkt 262001
and improved testing approaches
applicable to the needs of U.S. Federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative test methods
and strategies for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
Dated: May 3, 2024
Richard P. Woychik,
Director, National Institute of Environmental
Health Sciences and National Toxicology
Program, National Institutes of Health.
[FR Doc. 2024–10061 Filed 5–7–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Resilience to
AD.
Date: June 5, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maurizio Grimaldi, M.D.,
Ph.D., Scientific Review Officer, National
Institutes of Health, National Institute on
Aging, Gateway Building, 7201 Wisconsin,
ROOM 2C218, Bethesda, MD 20892, 301–
496–9374, grimaldim2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
38907
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK X01 Central
Repository Non-Renewable Sample Access
Review Meeting.
Date: July 11, 2024.
Time: 2:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7345,
6707 Democracy Boulevard, Bethesda, MD
20892–5452, (301) 594–8895, rushingp@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 2, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10016 Filed 5–7–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: May 2, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2024–10019 Filed 5–7–24; 8:45 am]
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
BILLING CODE 4140–01–P
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Center for Scientific Review; Notice of
Closed Meetings
E:\FR\FM\08MYN1.SGM
08MYN1
Agencies
[Federal Register Volume 89, Number 90 (Wednesday, May 8, 2024)]
[Notices]
[Pages 38906-38907]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10061]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee on the Validation of
Alternative Methods; Notice of Public Meeting; Request for Public Input
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Interagency Coordinating Committee on the Validation of
Alternative Methods (ICCVAM) will hold a public forum to share
information and facilitate direct communication of ideas and
suggestions from stakeholders. Interested persons may attend in person
or view the meeting remotely by webcast. Time will be set aside for
questions and public statements on the topics discussed. Registration
is requested for attending in person and required for viewing the
webcast. Registration is also required for presenting oral statements,
whether in person or online. Information about the meeting and
registration are available at https://ntp.niehs.nih.gov/go/iccvamforum-2024.
DATES:
Meeting: May 20, 2024, 1 p.m. to approximately 5 p.m. EDT; Tuesday,
May 21, 2024, 9 a.m. to approximately 4:30 p.m. EDT.
Registration for Onsite Meeting: Deadline is May 17, 2024.
Registration for Webcast: Deadline is May 21, 2024.
Registration for Oral Statements: Deadline is May 15, 2024.
Registration to attend in person is requested; registration to view
the webcast and to present oral public statements (in person or online)
is required.
ADDRESSES:
Meeting Location: William H. Natcher Conference Center, National
Institutes of Health (NIH), Bethesda, MD 20892.
Meeting web page: Registration and other meeting materials are at
https://ntp.niehs.nih.gov/go/iccvamforum-2024. A preliminary agenda
will be posted on this page by May 3.
FOR FURTHER INFORMATION CONTACT: Dr. Nicole Kleinstreuer, Director,
National Toxicology Program Interagency Center for the Evaluation of
Alternative Toxicological Methods (NICEATM), email:
[email protected], telephone: 984-287-3150.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM, a congressionally mandated committee,
coordinates the development and validation of alternative testing
strategies that protect human health and the environment while
replacing, reducing, or refining animal use.
ICCVAM's goals include promotion of national and international
partnerships between governmental and nongovernmental groups, including
academia, industry, advocacy groups, and other key stakeholders. To
foster these partnerships ICCVAM initiated annual public forums in 2014
to share information and facilitate direct communication of ideas and
suggestions from stakeholders (79 FR 25136).
This year's meeting will be held on May 20 and 21, 2024. NICEATM
and ICCVAM members will give presentations on current activities
related to the development and validation of alternative test methods
and approaches.
There will be opportunities for participants to ask clarifying or
follow-up questions of the ICCVAM members about their presentations.
Instructions for submitting these questions will be provided to webcast
viewers prior to the event. The agenda will also include time for
public oral statements relevant to the ICCVAM mission and current
activities from participants who have registered to do so in advance.
Preliminary Agenda and Other Meeting Information: A preliminary
agenda will be posted by May 3 at https://ntp.niehs.nih.gov/go/iccvamforum-2024. Interested individuals are encouraged to visit this
web page to stay abreast of the most current meeting information.
Meeting and Registration: This meeting is open to the public. The
public may attend the meeting at NIH, where attendance is limited only
by the space available, or view remotely by webcast. Those planning to
attend the meeting in person are encouraged to register at https://ntp.niehs.nih.gov/go/iccvamforum-2024 by May 15, 2024, to facilitate
planning for appropriate meeting space. Registration for the webcast is
required and is open through 4:30 p.m. EDT on May 21, 2024, at https://ntp.niehs.nih.gov/go/iccvamforum-2024. Registrants will receive
instructions on how to access and participate in the webcast in the
email confirming their registration.
NIH visitor and security information is available at https://www.nih.gov/about/visitor/index.htm. Individuals with disabilities who
need accommodation to participate in this event should contact Nicole
Kleinstreuer at phone: 919-407-1609 or email:
[email protected]. TTY users should contact the Federal TTY
Relay Service at 800-877-8339. Requests should be made at least five
business days in advance of the event.
Request for Oral Public Statements: In addition to time for
clarifying or follow-up questions following scheduled presentations,
time will be allotted during the meeting for oral public statements
with associated slides on topics relevant to ICCVAM's mission. Separate
registration for those wishing to provide public statements is required
and is open through May 15, 2024, at https://ntp.niehs.nih.gov/go/iccvamforum-2024. Any meeting attendee or webcast viewer may ask
clarifying questions during the appropriate times in the agenda. The
additional registration is only required for those who wish to give
separate public statements. The number and length of presentations may
be limited based on available time. Submitters will be identified by
their name and affiliation and/or sponsoring organization, if
applicable. Participants registered to present oral public statements
must email their statement to [email protected] by May 15,
2024, to allow time for review by NICEATM and ICCVAM and posting to the
meeting page prior to the forum. Persons submitting public statements
and/or associated slides should include their name, affiliation (if
any), mailing address, telephone, email, and sponsoring organization
(if any) with the document. Guidelines for public statements are at
https://ntp.niehs.nih.gov/ntp/about_ntp/guidelines_public_comments_508.pdf. Persons presenting oral public
statements will be contacted to arrange the logistics of their
presentations. Presenters should plan for their presentation to run
seven minutes or less; each public statement presentation will be
followed by up to three minutes to allow for clarifying or follow-up
questions. Time allotted for presentations and follow-up questions may
be reduced depending on the time available.
Written statements on topics relevant to ICCVAM's mission may be
submitted to support an oral public statement or as standalone
documents. These should be emailed to [email protected] by
May 15, 2024. Public statements received prior to the May 15
[[Page 38907]]
deadline will be distributed to NICEATM and ICCVAM members before the
meeting. Written public statements received after the deadline may be
reviewed by NICEATM and ICCVAM at a future date. Materials submitted to
accompany oral public statements or standalone written statements
should include the submitters name, affiliation (if any), mailing
address, telephone, email, and sponsoring organization (if any) with
the document. Guidelines for public statements are at https://ntp.niehs.nih.gov/ntp/about_ntp/guidelines_public_comments_508.pdf.
Responses to this notice are voluntary. No proprietary, classified,
confidential, or sensitive information should be included in statements
submitted in response to this notice or presented during the meeting.
This request for input is for planning purposes only and is not a
solicitation for applications or an obligation on the part of the U.S.
Government to provide support for any ideas identified in response to
the request. Please note that the U.S. Government will not pay for the
preparation of any information submitted or for its use of that
information.
Background Information on ICCVAM and NICEATM: ICCVAM is an
interagency committee composed of representatives from 17 Federal
regulatory and research agencies that require, use, generate, or
disseminate toxicological and safety testing information. ICCVAM
conducts technical evaluations of new, revised, and alternative safety
testing methods and integrated testing strategies with regulatory
applicability. ICCVAM also promotes the scientific validation and
regulatory acceptance of testing methods that more accurately assess
the safety and hazards of chemicals and products and replace, reduce,
or refine animal use.
The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l-3) establishes
ICCVAM as a permanent interagency committee of the National Institute
of Environmental Health Sciences and provides the authority for ICCVAM
involvement in activities relevant to the development of alternative
test methods. Additional information about ICCVAM can be found at
https://ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM, provides scientific and operational
support for ICCVAM-related activities, and conducts and publishes
analyses and evaluations of data from new, revised, and alternative
testing approaches. NICEATM and ICCVAM work collaboratively to evaluate
new and improved testing approaches applicable to the needs of U.S.
Federal agencies. NICEATM and ICCVAM welcome the public nomination of
new, revised, and alternative test methods and strategies for
validation studies and technical evaluations. Additional information
about NICEATM can be found at https://ntp.niehs.nih.gov/go/niceatm.
Dated: May 3, 2024
Richard P. Woychik,
Director, National Institute of Environmental Health Sciences and
National Toxicology Program, National Institutes of Health.
[FR Doc. 2024-10061 Filed 5-7-24; 8:45 am]
BILLING CODE 4140-01-P